Covovax

India has recorded 12,193 fresh COVID-19 cases in a span of 24 hours, with the number of active cases of the infection going up to 67,556, the Union health ministry said on Saturday.

Adar Poonawalla advises elderly to mask up, take Covovax booster as COVID cases rise

Proposing the uptake of newly approved COVID vaccine, the CEO of Serum Institute said Omicron XBB & its variants can be severe for the elderly.

Covid jab Covovax as heterologous booster to be available on CoWIN soon at Rs 225

Covovax can be administered to those who have already vaccinated with Covishield or Covaxin.

Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults

The letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) on March 27, they said.

Moneycontrol Daily: Your Essential 7

A daily round-up of the most interesting articles to help jump-start the day.

SII seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults

The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two doses of either Covishield or Covaxin.

DCGI approves market authorisation for SII's Covid vaccine Covovax as heterologous booster dose

The DCGI's approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO).

COVID-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla

"Covovax will be approved as a booster in the next 10-15 days. It is actually the best booster because it works very well against Omicron, more than Covishield," said Poonawalla.

COVID-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla

He said everyone was looking at India, not just in terms of healthcare but because the country managed to take care of a huge and diverse population and also helped 70 to 80 nations during the COVID-19 pandemic.

Serum Institute seeks drug regulator's approval for market authorisation of its Covid vaccine as booster dose

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation.

DCGI panel to review on Friday SII applications for Covovax's use among kids aged 2-7 years, 7-11 years

The petitions of Serum Institute of India seeking emergency use authorization to use Covovax among children aged two to seven and seven to eleven will be reviewed by the topic expert committee on COVID-19 of India's drug regulator on Friday, according to official sources.

Covid-19: 10 crore doses of SII's Covovax approved for exports by govt lab, stock rolled out for teens

Covovax, the Covid-19 vaccine manufactured by the Serum Institute of India under licence from US firm Novavax, will be available at Rs 225 per dose, excluding taxes, at private healthcare facilities.

COVID-19 Vaccination India | Covovax is now available for children aged 12-17 years: Adar Poonawalla

Covovax is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of over 90 percent, Poonawalla said while making the announcement on Twitter.

SII's COVID-19 vaccine Covovax now available for 12-17 age group at private centres

A dose of Covovax will cost Rs 900 plus GST at private vaccination centres, in addition to a hospital service charge of Rs 150.

Moneycontrol Selects: Top stories this evening

Our specially curated package of the most interesting articles of the day will help you stay at the top of your game.

COVID-19 update | NTAGI recommends Covovax for use in 12-17-year-olds in India

This is the Indian version of the COVID-19 vaccine, manufactured by the the US based Novavax.

For future orders, SII to provide free replacement if vaccine expires: Adar Poonawalla

"In 10-14 days, Covovax can be available on CoWin at about Rs 900 plus tax," the SII chief executive said.

COVID-19 update | Govt panel recommends inclusion of Covovax in vaccine drive for those aged 12 and above

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, subject to certain conditions, on March 9.

India's drugs regulator gives nod to phase-3 clinical trial of COVID vaccine Covovax

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) had, on March 5, recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose in adults who have been fully vaccinated with either Covaxin or Covishield at least three months ago.

Serum Institute of India seeks Covovax's inclusion in Covid vaccination drive for 12 years and above

The Pune-based SII said it wants to provide Covovax to private hospitals at Rs 900 per dose plus GST and is also waiting for directions to supply the vaccine to the Centre but has not mentioned the price.

COVID-19 vaccine: Govt panel recommends permission for phase-3 trial of Covovax as booster dose in adults

Covovax is manufactured by technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation and has also been granted emergency use listing by WHO.

Govt panel recommends EUA for COVID vaccine Covovax for 12-17 age group

The Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Friday deliberated on SII’s application and recommended granting EUA to Covovax.

Serum Institute seeks EUA for its Covovax vaccine for 12-17 years age group

In the application for emergency use authorisation (EUA) for the 12-17 year age group, Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, is learnt to have stated that data from two studies on about 2,707 individuals aged 12 to 17 years show Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group.

Govt mulls new vaccines as immunisation drive will likely extend to 12-14-year-olds

The Covid working group of the National Technical Advisory Group on Immunisation is set to discuss this on February 5.

Covid-19 booster shot: How safe and effective is the mix-and-match third dose?

Experts seem to be of the view that using different kinds of vaccines or mixing-and-matching vaccines is quite safe. The 'mixed' third dose's effectiveness is still being studied though.